Voya Financial (VOYA) Q3 Earnings and Revenues Top Estimates


The Zacks Medical sector has slightly outperformed the S&P 500 in 2022, down 18%.

A widely-popular company in the realm, AstraZeneca PLC AZN, is slated to unveil quarterly earnings on November 10th, before market open.

AstraZeneca is one of the largest biopharmaceutical companies in the world. Its business can be broken down into separate lines based on therapeutic classes, including cardiovascular, respiratory, immunology, oncology, rare diseases, and others. 

As it stands, the company carries a Zacks Rank #3 (Hold) paired with an overall VGM Score of a B.

How does everything else stack up heading into the release? Let’s find out.

Share Performance & Valuation

AZN shares have been a bright spot in an otherwise dim market in 2022, up nearly 8% and visibly outperforming the general market.

Image Source: Zacks Investment Research

Over the last three months, shares have continued on their market-beating trajectory, declining roughly 7% vs. the S&P 500’s decline of more than 9%.

Zacks Investment Research
Image Source: Zacks Investment Research

Shares trade at an 18.5X forward earnings multiple, nicely beneath the 22.3X five-year median and reflecting a 27% discount relative to its Zacks Medical sector.

The company sports a Style Score of a B.

Zacks Investment Research
Image Source: Zacks Investment Research

Quarterly Estimates

Analysts have been bullish regarding their earnings outlook, with four positive earnings estimate revisions hitting the tape over the last several months. The Zacks Consensus EPS Estimate of $0.77 indicates an improvement of more than 40% Y/Y.

Zacks Investment Research
Image Source: Zacks Investment Research

AstraZeneca’s top-line also appears to be in good health; the Zacks Consensus Sales Estimate of $11 billion suggests an uptick of more than 11% from year-ago quarterly sales of $9.9 billion.

Quarterly Performance

AZN has been on a strong earnings streak, exceeding revenue and earnings estimates in each of its last three quarters.

Just in its latest print, the company penciled in a sizable 10.3% EPS beat paired with a 3.2% sales surprise. Below is a chart illustrating the company’s revenue on a quarterly basis.

Zacks Investment Research
Image Source: Zacks Investment Research

Putting Everything Together

AZN shares have outperformed the general market across several timeframes in 2022, indicating that buyers have stepped up.

The company’s forward earnings multiple is well below its five-year median and Zacks Medical sector average.

Analysts have been bullish over the last several months, with estimates indicating Y/Y upticks in both revenue and earnings.

The company has consistently exceeded quarterly estimates, exceeding both revenue and EPS expectations in each of its last three releases.

Heading into the print, AstraZeneca PLC AZN carries a Zacks Rank #3 (Hold) with an Earnings ESP Score of 2.1%.

Zacks Names “Single Best Pick to Double”

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Image and article originally from www.nasdaq.com. Read the original article here.

By Zacks